Agios Pharmaceuticals (AGIO) Stock Rating Kept by Credit Suisse; The $80 Target Indicates 1.54% Potential; Baker Avenue Asset Management LP Increased International Business Machs Com (IBM) Position

February 15, 2018 - By Louis Casey

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals has $132 highest and $47 lowest target. $75.64’s average target is -4.00% below currents $78.79 stock price. Agios Pharmaceuticals had 41 analyst reports since July 23, 2015 according to SRatingsIntel. SunTrust maintained it with “Buy” rating and $80.0 target in Sunday, November 19 report. RBC Capital Markets maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) rating on Wednesday, November 1. RBC Capital Markets has “Buy” rating and $80.0 target. The company was maintained on Tuesday, August 1 by Oppenheimer. The rating was maintained by Roth Capital on Monday, November 9 with “Neutral”. On Wednesday, March 30 the stock rating was initiated by SunTrust with “Buy”. On Wednesday, March 2 the stock rating was initiated by Janney Capital with “Neutral”. The rating was maintained by Cowen & Co with “Buy” on Tuesday, August 1. On Tuesday, June 6 the stock rating was maintained by Cowen & Co with “Buy”. The firm has “Buy” rating given on Wednesday, May 18 by Suntrust Robinson. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Buy” rating given on Monday, September 18 by J.P. Morgan.

Baker Avenue Asset Management Lp increased International Business Machs Com (IBM) stake by 6.25% reported in 2017Q3 SEC filing. Baker Avenue Asset Management Lp acquired 2,335 shares as International Business Machs Com (IBM)’s stock declined 15.88%. The Baker Avenue Asset Management Lp holds 39,718 shares with $5.76 million value, up from 37,383 last quarter. International Business Machs Com now has $143.79B valuation. The stock increased 0.36% or $0.55 during the last trading session, reaching $155.31. About 1.18 million shares traded. International Business Machines Corporation (NYSE:IBM) has risen 4.86% since February 15, 2017 and is uptrending. It has underperformed by 11.84% the S&P500.

Since August 22, 2017, it had 0 buys, and 22 selling transactions for $25.02 million activity. Another trade for 2,146 shares valued at $144,276 was made by Biller Scott on Monday, October 2. 13,000 shares valued at $1.02 million were sold by Schenkein David P on Thursday, February 1. 4,000 shares were sold by Cantley Lewis Clayton Jr., worth $227,400 on Tuesday, August 22. Hoerter Steven L. had sold 25,000 shares worth $1.87 million on Tuesday, January 23. Bowden Christopher had sold 6,000 shares worth $390,000. Another trade for 2,150 shares valued at $161,250 was made by Alenson Carman on Friday, January 12.

The stock increased 1.06% or $0.82 during the last trading session, reaching $78.79. About 75,146 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 8.52% since February 15, 2017 and is uptrending. It has underperformed by 8.18% the S&P500.

Investors sentiment decreased to 1.21 in 2017 Q3. Its down 0.83, from 2.04 in 2017Q2. It is negative, as 22 investors sold Agios Pharmaceuticals, Inc. shares while 44 reduced holdings. 29 funds opened positions while 51 raised stakes. 44.69 million shares or 0.07% less from 44.72 million shares in 2017Q2 were reported. Bnp Paribas Arbitrage owns 12,216 shares for 0% of their portfolio. Citigroup, New York-based fund reported 3,097 shares. 67,038 are owned by California State Teachers Retirement Systems. Btg Pactual Asset Mngmt has 0.17% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 8,023 shares. Barclays Public Limited Com owns 28,736 shares for 0% of their portfolio. Bb Biotech Ag reported 2.75 million shares. Tarbox Family Office reported 0% stake. Fifth Third Bancorporation invested in 0% or 689 shares. Weiss Asset L P stated it has 2,997 shares. Qs Limited Liability has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 2,800 shares. Ray Gerald L And Assocs Limited holds 0.25% or 29,465 shares. Ameriprise Fin invested in 57,504 shares. Swiss Bancorp owns 68,460 shares. 729,714 are held by Guardian Tru Company. Oppenheimer And Incorporated has invested 0.04% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.39 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Since January 31, 2018, it had 1 buy, and 0 sales for $99,659 activity. On Wednesday, January 31 the insider WADDELL FREDERICK H bought $99,659.

Among 33 analysts covering International Business Machines (NYSE:IBM), 13 have Buy rating, 4 Sell and 16 Hold. Therefore 39% are positive. International Business Machines had 123 analyst reports since July 21, 2015 according to SRatingsIntel. S&P Research maintained the stock with “Buy” rating in Wednesday, October 21 report. Citigroup maintained the shares of IBM in report on Tuesday, October 18 with “Neutral” rating. The rating was initiated by Berenberg with “Sell” on Tuesday, April 4. The rating was maintained by Bank of America with “Buy” on Thursday, January 18. The stock of International Business Machines Corporation (NYSE:IBM) earned “Hold” rating by Guggenheim on Thursday, July 13. As per Tuesday, July 19, the company rating was maintained by Drexel Hamilton. GBH Insights maintained International Business Machines Corporation (NYSE:IBM) rating on Thursday, January 18. GBH Insights has “Buy” rating and $180.0 target. As per Wednesday, July 19, the company rating was maintained by UBS. The company was maintained on Tuesday, April 19 by Bernstein. The firm has “Buy” rating given on Thursday, October 5 by Stifel Nicolaus.

Investors sentiment increased to 0.74 in 2017 Q3. Its up 0.02, from 0.72 in 2017Q2. It is positive, as 70 investors sold IBM shares while 676 reduced holdings. 100 funds opened positions while 451 raised stakes. 519.10 million shares or 2.22% less from 530.91 million shares in 2017Q2 were reported. Vista Capital Prns stated it has 1,638 shares. Gotham Asset Ltd Liability Co has invested 0.51% of its portfolio in International Business Machines Corporation (NYSE:IBM). Godshalk Welsh Cap Mngmt holds 5,350 shares or 0.78% of its portfolio. Associated Banc has invested 0.27% in International Business Machines Corporation (NYSE:IBM). Zeke Advsrs Ltd Liability Company holds 13,411 shares. King Luther Cap Mgmt owns 172,882 shares. Crossvault Cap Lc invested in 8,045 shares or 0.67% of the stock. 3,812 were accumulated by Northstar Gru. Richard C Young Com Ltd reported 26,817 shares stake. Mayo Inv Advisers Ltd Liability Co holds 0.16% or 2,400 shares. Moreover, Cap Wealth Planning Ltd Com has 0.29% invested in International Business Machines Corporation (NYSE:IBM) for 2,548 shares. Johnson Invest Counsel Inc holds 0.17% or 44,312 shares. Peak Asset Mngmt holds 0.17% or 3,293 shares in its portfolio. 9,533 were accumulated by Marble Harbor Counsel Limited Liability. 47,372 were accumulated by Cohen Capital Management Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: